| CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, ... Molecular therapy 25 (9), 2214-2224, 2017 | 454 | 2017 |
| Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma MD Carlos A. Ramos, MD Natalie S. Grover, MD Anne W. Beaven, ... Journal of Clinical Oncology 38 (21), 2020 | 288 | 2020 |
| In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas CA Ramos, R Rouce, CS Robertson, A Reyna, N Narala, G Vyas, B Mehta, ... Molecular Therapy 26 (12), 2727-2737, 2018 | 234 | 2018 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, ... Nature communications 11 (1), 3549, 2020 | 116 | 2020 |
| Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells M Tanaka, H Tashiro, B Omer, N Lapteva, J Ando, M Ngo, B Mehta, ... Clinical Cancer Research 23 (14), 3499-3509, 2017 | 84 | 2017 |
| Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies LQC Hill, RH Rouce, TS Smith, L Yang, M Srinivasan, H Zhang, ... Blood 134, 199, 2019 | 61 | 2019 |
| Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results A Heczey, X Xu, AN Courtney, G Tian, GA Barragan, L Guo, CM Amador, ... Nature Medicine 29 (6), 1379-1388, 2023 | 34 | 2023 |
| Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies N Watanabe, F Mo, R Zheng, R Ma, VC Bray, DG van Leeuwen, ... Molecular Therapy 31 (1), 24-34, 2023 | 31 | 2023 |
| CD5 CAR T-cells for treatment of patients with relapsed/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity LQ Hill, RH Rouce, TS Smith, L Yang, M Srinivasan, H Zhang, S Perconti, ... Biology of Blood and Marrow Transplantation 26 (3), S237, 2020 | 18 | 2020 |
| Early signals of anti-tumor efficacy and safety with autologous CD5. CAR T-cells in patients with refractory/relapsed T-cell lymphoma RH Rouce, LQC Hill, TS Smith, L Yang, B Boriskie, M Srinivasan, H Zhang, ... Blood 138, 654, 2021 | 12 | 2021 |
| CD30. CAR-modified Epstein-Barr virus-specific T cells (CD30. CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma DH Quach, CA Ramos, PD Lulla, S Sharma, HR Ganesh, N Nouraee, ... Blood 140 (Supplement 1), 412-414, 2022 | 9 | 2022 |
| Quality and seed yield of garden pea (Pisum sativum) cultivars as influenced by date of planting and phosphorus levels. BN Sinha, BS Mehta, M Joydip Indian Journal of Agricultural Sciences 70 (4), 248-249, 2000 | 8 | 2000 |
| Safety and efficacy of off-the-shelf cd30. car-modified epstein-barr virus-specific t cells in patients with cd30-positive lymphoma DH Quach, CA Ramos, PD Lulla, S Sharma, HR Ganesh, YF Hadidi, ... Blood 138, 1763, 2021 | 7 | 2021 |
| A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma 62nd ASH Annual Meeting & Exposition 704 (Immunotherapies), Poster 3268, 2020 | 6* | 2020 |
| Effect of planting dates and nitrogen levels on yield and quality attributes of cucumber SK Sharma, BS Mehta, KB Rastogi Indian Journal of Horticulture 54 (2), 160-162, 1997 | 6 | 1997 |
| OFF‐THE‐SHELF CD30. CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30. CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) CA Ramos, DH Quach, PD Lulla, RH Rouce, S Sharma, HR Ganesh, ... Hematological Oncology 41, 83-85, 2023 | 5 | 2023 |
| Effect of planting time and spacing on some indeterminate tomato cultivars in mid hills. RK Bhardwaj, BS Mehta, UK Kohli | 5 | 1995 |
| Effect of NPK on the plant growth, flowering and yield of cultivar Solar gaal (Lycopersicon esculentum Mill) BS Mehta, SS Saini Haryana J. Hort. Sci 15, 91-94, 1986 | 5 | 1986 |
| Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL. LQC Hill, RH Rouce, TS Smith, B Boriskie, M Srinivasan, SG Thakkar, ... Journal of Clinical Oncology 41 (16_suppl), 7002-7002, 2023 | 4 | 2023 |
| Antitumor efficacy and safety of unedited autologous CD5. CAR T cells in relapsed/refractory mature T-cell lymphomas LQC Hill, RH Rouce, MJ Wu, T Wang, R Ma, H Zhang, B Mehta, ... Blood 143 (13), 1231-1241, 2024 | 3 | 2024 |
Helen HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and TexasEmail yang diverifikasi di bcm.edu
